The U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED), regardless of disease activity or duration.
This approval marks an important milestone for the TED community and reflects years of research, collaboration, and the participation of hundreds of individuals in clinical trials.
To learn more, visit Lumvoa.com.
